Literature DB >> 22492547

Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.

Yves Sabbagh1, Fabiana Giorgeti Graciolli, Stephen O'Brien, Wen Tang, Luciene Machado dos Reis, Susan Ryan, Lucy Phillips, Joseph Boulanger, Wenping Song, Christina Bracken, Shiguang Liu, Steven Ledbetter, Paul Dechow, Maria Eugenia F Canziani, Aluizio B Carvalho, Vanda Jorgetti, Rosa M A Moyses, Susan C Schiavi.   

Abstract

Chronic kidney disease-mineral bone disorder (CKD-MBD) is defined by abnormalities in mineral and hormone metabolism, bone histomorphometric changes, and/or the presence of soft-tissue calcification. Emerging evidence suggests that features of CKD-MBD may occur early in disease progression and are associated with changes in osteocyte function. To identify early changes in bone, we utilized the jck mouse, a genetic model of polycystic kidney disease that exhibits progressive renal disease. At 6 weeks of age, jck mice have normal renal function and no evidence of bone disease but exhibit continual decline in renal function and death by 20 weeks of age, when approximately 40% to 60% of them have vascular calcification. Temporal changes in serum parameters were identified in jck relative to wild-type mice from 6 through 18 weeks of age and were subsequently shown to largely mirror serum changes commonly associated with clinical CKD-MBD. Bone histomorphometry revealed progressive changes associated with increased osteoclast activity and elevated bone formation relative to wild-type mice. To capture the early molecular and cellular events in the progression of CKD-MBD we examined cell-specific pathways associated with bone remodeling at the protein and/or gene expression level. Importantly, a steady increase in the number of cells expressing phosphor-Ser33/37-β-catenin was observed both in mouse and human bones. Overall repression of Wnt/β-catenin signaling within osteocytes occurred in conjunction with increased expression of Wnt antagonists (SOST and sFRP4) and genes associated with osteoclast activity, including receptor activator of NF-κB ligand (RANKL). The resulting increase in the RANKL/osteoprotegerin (OPG) ratio correlated with increased osteoclast activity. In late-stage disease, an apparent repression of genes associated with osteoblast function was observed. These data confirm that jck mice develop progressive biochemical changes in CKD-MBD and suggest that repression of the Wnt/β-catenin pathway is involved in the pathogenesis of renal osteodystrophy.
Copyright © 2012 American Society for Bone and Mineral Research.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22492547     DOI: 10.1002/jbmr.1630

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  93 in total

1.  Associations between the levels of sclerostin, phosphate, and fibroblast growth factor-23 and treatment with vitamin D in hemodialysis patients with low intact PTH level.

Authors:  Y Asamiya; A Yajima; S Shimizu; S Otsubo; K Tsuchiya; K Nitta
Journal:  Osteoporos Int       Date:  2014-11-04       Impact factor: 4.507

2.  The Authors Reply.

Authors:  Katherine Wesseling-Perry
Journal:  Kidney Int       Date:  2015-09       Impact factor: 10.612

Review 3.  Bone Disease in CKD in Children.

Authors:  Fernando Santos; Lucas Díaz-Anadón; Flor A Ordóñez; Dieter Haffner
Journal:  Calcif Tissue Int       Date:  2021-01-16       Impact factor: 4.333

4.  Is serum sclerostin a marker of atherosclerosis in patients with chronic kidney disease-mineral and bone disorder?

Authors:  Andreja Figurek; Goce Spasovski
Journal:  Int Urol Nephrol       Date:  2018-07-20       Impact factor: 2.370

Review 5.  WNT signaling in bone homeostasis and disease: from human mutations to treatments.

Authors:  Roland Baron; Michaela Kneissel
Journal:  Nat Med       Date:  2013-02-06       Impact factor: 53.440

6.  Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.

Authors:  Toshifumi Sugatani; Olga A Agapova; Yifu Fang; Alycia G Berman; Joseph M Wallace; Hartmut H Malluche; Marie-Claude Faugere; William Smith; Victoria Sung; Keith A Hruska
Journal:  Kidney Int       Date:  2016-09-22       Impact factor: 10.612

7.  Chronic Kidney Disease Is Associated With Greater Bone Marrow Adiposity.

Authors:  Gina N Woods; Susan K Ewing; Sigurdur Sigurdsson; Deborah M Kado; Joachim H Ix; Trisha F Hue; Gudny Eiriksdottir; Kaipin Xu; Vilmundur Gudnason; Thomas F Lang; Eric Vittinghoff; Tamara B Harris; Clifford J Rosen; Xiaojuan Li; Ann V Schwartz
Journal:  J Bone Miner Res       Date:  2018-08-27       Impact factor: 6.741

8.  Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients?

Authors:  S Pelletier; C B Confavreux; J Haesebaert; F Guebre-Egziabher; J Bacchetta; M-C Carlier; L Chardon; M Laville; R Chapurlat; G M London; M-H Lafage-Proust; D Fouque
Journal:  Osteoporos Int       Date:  2015-04-25       Impact factor: 4.507

9.  Only minor differences in renal osteodystrophy features between wild-type and sclerostin knockout mice with chronic kidney disease.

Authors:  Daniel Cejka; Diego Parada-Rodriguez; Stefanie Pichler; Rodrig Marculescu; Ina Kramer; Michaela Kneissel; Thomas Gross; Andreas Reisinger; Dieter Pahr; Marie-Claude Monier-Faugere; Martin Haas; Hartmut H Malluche
Journal:  Kidney Int       Date:  2016-08-12       Impact factor: 10.612

Review 10.  Hormonal and systemic regulation of sclerostin.

Authors:  Matthew T Drake; Sundeep Khosla
Journal:  Bone       Date:  2016-12-10       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.